IP Verse

Controlled Release Pharmaceutical Composition - EP2554168

The patent EP2554168 was granted to Astellas Pharma on Jan 24, 2018. The application was originally filed on Mar 28, 2011 under application number EP11762748A. The patent is currently recorded with a legal status of "Revoked".

EP2554168

ASTELLAS PHARMA
Application Number
EP11762748A
Filing Date
Mar 28, 2011
Status
Revoked
Jul 10, 2020
Grant Date
Jan 24, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHEROct 24, 2018HAMM & WITTKOPP -
HEXALOct 24, 2018BEST -
LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBOct 24, 2018KALHAMMER -
STADA ARZNEIMITTELOct 24, 2018KERNEBECK -

Patent Citations (69) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONJP2005162736
DESCRIPTIONJP2005162737
DESCRIPTIONJP2832248B
DESCRIPTIONUS3133132
DESCRIPTIONUS3173876
DESCRIPTIONUS3276586
DESCRIPTIONUS3541005
DESCRIPTIONUS3541006
DESCRIPTIONUS3546142
DESCRIPTIONUS3845770
DESCRIPTIONUS3865108
DESCRIPTIONUS3916899
DESCRIPTIONUS3995631
DESCRIPTIONUS4002173
DESCRIPTIONUS4008719
DESCRIPTIONUS4077407
DESCRIPTIONUS4088864
DESCRIPTIONUS4111202
DESCRIPTIONUS4160020
DESCRIPTIONUS4207893
DESCRIPTIONUS4327725
DESCRIPTIONUS4519801
DESCRIPTIONUS4578075
DESCRIPTIONUS4681583
DESCRIPTIONUS4839177
DESCRIPTIONUS4994276
DESCRIPTIONUS5007790
DESCRIPTIONUS5019397
DESCRIPTIONUS5128143
DESCRIPTIONUS5135757
DESCRIPTIONUS5156850
DESCRIPTIONUS5422123
DESCRIPTIONUS5582837
DESCRIPTIONUS5780057
DESCRIPTIONUS5972389
DESCRIPTIONUS6149940
DESCRIPTIONUS6340475
DESCRIPTIONWO2004041276
DESCRIPTIONWO9316686
DESCRIPTIONWO9406414
DESCRIPTIONWO9920607
INTERNATIONAL-SEARCH-REPORTJP2005162736
INTERNATIONAL-SEARCH-REPORTJP2005162737
INTERNATIONAL-SEARCH-REPORTJP2008532953
INTERNATIONAL-SEARCH-REPORTWO2004041276
INTERNATIONAL-SEARCH-REPORTWO2008084698
INTERNATIONAL-SEARCH-REPORTWO2010038690
INTERNATIONAL-SEARCH-REPORTWO9406414
OPPOSITIONEP0661045
OPPOSITIONEP1205190
OPPOSITIONEP1529526
OPPOSITIONEP1559427
OPPOSITIONEP1568361
OPPOSITIONEP2119442
OPPOSITIONEP2345410
OPPOSITIONUS2005100602
OPPOSITIONUS2005287185
OPPOSITIONUS5681582
OPPOSITIONUS6368628
OPPOSITIONWO2009019599
OPPOSITIONWO2009052353
OPPOSITIONWO2010038690
OTHEREP1205190
OTHEREP1559427
OTHEREP2345410
OTHERWO2010038690
SEARCHEP1440969
SEARCHEP1559427
SEARCHUS6346532

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Encyclopedia of Polymer Science and Technology, INTERSCIENCE PUBLISHERS INC., (1964), vol. 3, pages 325 - 354-
DESCRIPTION- SANTUS; BAKER, "Osmotic drug delivery: a review of the patent literature", JOURNAL OF CONTROLLED RELEASE, (1995), vol. 35, pages 1 - 21-
OPPOSITION- Anderssona Karl-Erik et al., "Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence", Current Opinion in Urology, (20090000), vol. 19, pages 380 - 394, XP055525123-
OPPOSITION- Chapple C. R. et al., "CLINICAL PROOF OF CONCEPT STUDY (BLOSSOM) SHOWS NOVELBETA-3 ADRENOCEPTOR AGONIST YM17B IS EFFECTIVE AND WELLTOLERATED IN THE TREATMENT OF SYMPTOMS OF OVERACTIVEBLADDER", Eur. Urol. Suppl., (20080000), vol. 7, no. 3, page 239, XP055525113-
OPPOSITION- CHAPPLE et al., "CLINICAL PROOF OF CONCEPT STUDY (BLOSSOM) SHOWS NOVELBETA-3 ADRENOCEPTOR AGONIST YM17B IS EFFECTIVE AND WELLTOLERATED IN THE TREATMENT OF SYMPTOMS OF OVERACTIVEBLADDER", Eur. Urol. Suppl., (20080000), vol. 7, no. 3, page 239, XP055525113-
OPPOSITION- "Chapter 1", WEN H et al., Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice, John Wiley & Sons, (20100000), pages 1 - 9, XP055526862-
OPPOSITION- Christopher R. Chapple, "The Vevelopment of the Oral Controlled Absorption system (OCAS): A New Improved Formulation of Tamsulosin", European Urology Supplements, (20050000), vol. 4, pages 1 - 4, XP055525201-
OPPOSITION- C.R. CHAPPLE, "The Development of the Oral Controlled Absorption System (OCAS@): A New Improved Formulation of Tamsuiosin", European Urology Supplements, (20051000), vol. 4, no. 7, pages 1 - 4, XP027626789-
OPPOSITION- C. R. CHAPPLE, "The Development of the Oral ControlledAbsorption System (OCAS®): A New Improved Formulation of Tamsulosin", European Urology Supplements, (20051000), vol. 4, no. 7, pages 1 - 4, XP027626789-
OPPOSITION- "History of Changes for Study: NCT00662909Study to Test the Efficacy and Safety of the BetaM3 Agonist YM178 inPatients With Symptoms of Overactive Bladder", ClinicalTrials.gov archive, (20090520), pages 1 - 8, XP055525141-
OPPOSITION- "History of Changes for Study: NCT00689104Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 inSubjects With Symptoms of Overactive Bladder", ClinicalTrials.gov archive, (20100323), pages 1 - 8, XP055525148-
OPPOSITION- "History of Changes for Study: NCT00912964A Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder", ClinicalTrials.gov archive, (20100104), pages 1 - 8, XP055525143-
OPPOSITION- "History of Changes for Study: NCT00939757Study of the Effect of Food on the Pharmacokinetics of Mirabegron", ClinicalTrials.gov archive, Study NCT00939757, (20090803), pages 1 - 6, XP055525181-
OPPOSITION- "History of Changes for Study: NCT00940121 Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron", ClinicalTrials.gov archive, Study NCT00940121, (20090803), pages 1 - 8, XP055525156-
OPPOSITION- "History of Changes for Study: NCT00965926A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers", ClinicalTrials.gov archive, Study NCT00965926, (20091001), pages 1 - 6, XP055525163-
OPPOSITION- J.B. DRESSMAN et al., "Oral Drug Absorption: Prediction and Assessment", Drugs and the Pharmaceutical Sciences, (20000000), vol. 106, pages 183 - 228, XP055525188-
OPPOSITION- Jerome P. SkeHy et al., "IN VITRO AND IN VIVO TESTING AND CORRELATION FOR ORAL CONTROLLED/MODIFIED RELEASE DOSAGE FORMS", Journal of Controlled Release, (19900000), vol. 14, pages 95 - 106, XP055525205-
OPPOSITION- "Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section II (Pharmacokinetic and Clinical Evaluation)", COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP), (19990728), pages 1 - 12, XP055525212-
OPPOSITION- "Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus intravenous (IV) Mirabegron", ClinicalTrials.gov archive, NCT00940121, (20090714), pages 1 - 7, URL: https://clinicaltrials.gov/ct2/history/NCT00940121?V_1=View#StudyPageTop, XP055525723-
OPPOSITION- "Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron", ClinicalTrials.gov, NCT00940121, (20130703), pages 1 - 8, URL: https://clinicaltrials.gov/ct2/history/NCT00940121?V_2=View#StudyPageTop, XP055525156-
OPPOSITION- "Supporting information for pharmaceutical product registrations", CCDA. National institute of Food and Drug Safety Evaluation (NiFDS), (20091200), pages 1 - 121, XP055525705-
OPPOSITION- Siepmann F. et al, "Polymer blends for controlled release coatings", Journal of Controlled Release, (20081013), vol. 125, no. 1, pages 1 - 15, XP022375058
OPPOSITION- T. TAKASU et al., "Effect of (R)-2-(2-Aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective beta3-Adrenoceptor Agonist, on Bladder Function", J. Pharmacol. Exp. Ther., (20070000), vol. 321, no. 2, pages 642 - 647, XP008161740
OPPOSITION- KARL-ERIK ANDERSSON, "Prospective pharmacologic therapies for the overactive bladder", Therapeutic Advances in Urology, (20090600), vol. 1, no. 2, pages 71 - 83, XP055526839
OPPOSITION- MAUGER et al., "Intrinsic Dissolution Performance Testing of the USP Dissolution Apparatus 2 (Rotating Paddle) Using Modified Salicylic Acid Calibrator Tablets: Proof of Principle", Dissolution Technologies, (20030800), pages 6 - 15, XP055507647
OPPOSITION- Dimitrios Bikiaris et al, "New Aspects in Sustained Drug Release Formulations", Recent Patents on Drug Delivery & Formulation, (20071100), vol. 1, no. 3, pages 201 - 213, XP055526856
OPPOSITION- Himanshu Gupta et al, "Recent Trends in Oral Drug Delivery: A Review", Recent Patents on Drug Delivery & Formulation, (20090600), vol. 3, no. 2, pages 162 - 173, XP055526851

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents